B7-H4 Inhibitors
B7-H4 inhibitors encompass a diverse set of chemical compounds with the potential to modulate the expression and function of B7-H4, a checkpoint molecule involved in immune regulation. These inhibitors can be categorized into direct and indirect inhibitors based on their mode of action. Direct inhibitors like Thalidomide, BRD4770, and SD-208 target specific aspects of B7-H4 regulation. Thalidomide exhibits immunomodulatory effects, impacting pathways related to B7-H4 expression. BRD4770, by inhibiting BRD4, modulates gene expression patterns that may influence B7-H4. SD-208, a TGF-β receptor I inhibitor, indirectly affects B7-H4 by blocking the TGF-β signaling pathway. Indirect inhibitors, such as Methotrexate, DMXAA, and 5-Azacytidine, exert their influence through broader mechanisms. Methotrexate's anti-inflammatory and immunomodulatory effects may impact pathways associated with B7-H4. DMXAA, with anti-tumor properties, targets angiogenesis and inflammation pathways that may indirectly affect B7-H4. 5-Azacytidine, a DNA methyltransferase inhibitor, modulates epigenetic regulation, potentially influencing B7-H4 expression.
Leflunomide, Valproic Acid, and 2-Deoxyglucose (2-DG) represent additional indirect inhibitors with diverse mechanisms. Leflunomide, an immunomodulatory drug, may impact B7-H4 through its effects on immune cell proliferation. Valproic Acid, an HDAC inhibitor, modulates chromatin structure and gene expression, potentially influencing B7-H4. 2-DG, a glycolytic inhibitor, disrupts cellular metabolism, affecting pathways associated with immune regulation and B7-H4. Pyrimethamine and Epacadostat, with antimalarial and IDO1 inhibitory properties, respectively, provide further options for B7-H4 modulation. Pyrimethamine's immunomodulatory effects may impact B7-H4 expression, while Epacadostat, targeting the IDO1 pathway, influences immune regulation and B7-H4. Sunitinib, a receptor tyrosine kinase inhibitor, indirectly influences B7-H4 through its effects on angiogenesis and immune regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide is an immunomodulatory drug that indirectly influences B7-H4. It exhibits anti-inflammatory properties and inhibits angiogenesis, potentially impacting pathways related to B7-H4 expression. While the exact mechanism is not fully elucidated, Thalidomide's immunomodulatory effects may contribute to the modulation of B7-H4 in the context of immune responses and inflammation. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208 is a selective transforming growth factor-beta (TGF-β) receptor I (ALK5) inhibitor. By blocking the TGF-β signaling pathway, SD-208 indirectly impacts B7-H4 expression. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate is an antimetabolite and immunosuppressive drug that indirectly influences B7-H4. Its anti-inflammatory and immunomodulatory effects may impact pathways associated with B7-H4 expression. | ||||||
DMXAA | 117570-53-3 | sc-207592 sc-207592A | 5 mg 25 mg | $129.00 $590.00 | 1 | |
DMXAA (Vadimezan) is a compound with anti-tumor and anti-angiogenic properties. It indirectly influences B7-H4 by targeting pathways related to angiogenesis and inflammation. DMXAA's effects on the tumor microenvironment may lead to alterations in the expression of immune checkpoints, including B7-H4. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor that indirectly influences B7-H4 by targeting epigenetic regulation. As a demethylating agent, 5-Azacytidine can alter gene expression patterns, potentially affecting pathways associated with B7-H4. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide is an immunomodulatory drug that indirectly influences B7-H4. It inhibits dihydroorotate dehydrogenase (DHODH), impacting de novo pyrimidine synthesis and immune cell proliferation. Leflunomide's immunomodulatory effects may extend to pathways associated with B7-H4 expression, providing an indirect means to modulate B7-H4 levels in the context of immune responses and autoimmune diseases. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid is a histone deacetylase (HDAC) inhibitor that indirectly influences B7-H4 by targeting epigenetic regulation. By inhibiting HDAC enzymes, Valproic Acid modulates chromatin structure and gene expression patterns, potentially impacting pathways associated with B7-H4. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose (2-DG) is a glycolytic inhibitor that indirectly influences B7-H4. By disrupting cellular metabolism, 2-DG impacts pathways associated with immune regulation and may affect B7-H4 expression. The precise mechanism by which 2-DG modulates B7-H4 levels requires further investigation, but its influence on cellular metabolism suggests a potential role in controlling B7-H4 expression in the context of immune responses and cancer. | ||||||
Pyrimethamine | 58-14-0 | sc-208190 sc-208190A sc-208190B | 1 g 5 g 25 g | $80.00 $238.00 $825.00 | 5 | |
Pyrimethamine is an antimalarial drug that indirectly influences B7-H4. Its immunomodulatory effects, possibly related to its impact on folate metabolism, may influence pathways associated with B7-H4 expression. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib is a receptor tyrosine kinase inhibitor with anti-tumor properties. It indirectly influences B7-H4 by targeting pathways related to angiogenesis and immune regulation. Sunitinib's effects on the tumor microenvironment may lead to alterations in the expression of immune checkpoints, including B7-H4. | ||||||